Makita Naomasa
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Circ J. 2009 May;73(5):810-7. doi: 10.1253/circj.cj-09-0014. Epub 2009 Mar 31.
Mutations in the cardiac sodium channel gene SCN5A are responsible for a spectrum of hereditary arrhythmias, including type-3 long QT syndrome (LQT3), Brugada syndrome (BrS), conduction disturbance and sinus node dysfunction. These syndromes were originally regarded as independent entities with distinct clinical manifestations and biophysical properties, but recent evidence shows considerable clinical overlap, implying a new disease entity known as an overlap syndrome of cardiac sodium channelopathy. Class IC sodium-channel blockers often induced the BrS phenotype in some patients with LQT3, confirming the clinical overlap of LQT3 and BrS. It also raises a concern about the safety of the class IC drug and questions about the determinants of overlap. Here, an overview is given of current knowledge on the clinical features, prevalence, and molecular and biophysical mechanisms underlying overlap syndrome to gain more insight into this complex issue and generate better therapeutic strategies for patient management.
心脏钠通道基因SCN5A的突变是一系列遗传性心律失常的病因,包括3型长QT综合征(LQT3)、 Brugada综合征(BrS)、传导障碍和窦房结功能障碍。这些综合征最初被视为具有不同临床表现和生物物理特性的独立实体,但最近的证据表明它们在临床上有相当大的重叠,这意味着一种新的疾病实体,即心脏钠通道病重叠综合征。Ic类钠通道阻滞剂常可在一些LQT3患者中诱发BrS表型,这证实了LQT3和BrS在临床上的重叠。这也引发了对Ic类药物安全性的担忧以及关于重叠决定因素的疑问。在此,本文概述了重叠综合征的临床特征、患病率以及潜在的分子和生物物理机制方面的现有知识,以便更深入地了解这一复杂问题,并为患者管理制定更好的治疗策略。